Skip to content

This European website contains promotional content developed by CSL Behring for European healthcare professionals and includes references to CSL Behring medicines. Prescribing information and Adverse Event reporting can be found at the bottom of the page.

Haemevolution

Are You a Healthcare Professional?

This European website, initiated and developed by CSL Behring, contains product specific information and promotional content on gene therapy in haemophilia B and is intended for an international audience of European healthcare professionals only. For more detailed information on the use of the product in your country, please visit www.cslbehring.com.

Yes, I am a healthcare professional*

Enter Site

*CSL Behring is legally obliged to restrict this website to healthcare professionals only. By clicking “Yes, I am a healthcare professional”, you confirm this statement is true and you accept all liability related. If you are not a healthcare professional you can visit our disease awareness webpage: www.haemevolution.eu

References

  1. EU SmPC HEMGENIX® (European Medicine Agency, 2023)
  2. Pipe SW, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023;388:706-718.
  3. CSL Behring. First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission. Press release. 20 Feb 2023. Available at: https://newsroom.csl.com/2023-02-20-First-Gene-Therapy-for-Hemophilia-B,-CSLs-HEMGENIX-R-,-Approved-by-the-European-Commission. Accessed March 2023.
  4. Nathwani AC. Gene therapy for Haemophilia. Hematology Am Soc Hematol Educ Program. 2019;2019(1):1-8.
  5. Thornburg CD. Etranacogene dezaparvovec for hemophilia B gene therapy. Ther Adv Rare Dis. 2021;2:1–14.
  6. Rodríguez-Merchán EC, et al. Gene Therapy in Hemophilia: Recent Advances. Int. J. Mol. Sci. 2021;22:7647-67.
  7. Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for Haemophilia. Blood. 2019;133(5):407-414.
  8. Miesbach W, et al. Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B. Blood. 2018;131(9):1022-31.